三子止咳胶囊对COPD稳定期患者肺功能的改善作用及机制

发布时间：2019-05-15 00:56

【摘要】：目的观察三子止咳胶囊对慢性阻塞性肺疾病(COPD)稳定期患者肺功能的改善作用,探讨其可能的作用机制。方法将68例COPD稳定期患者随机分为观察组33例、对照组35例。观察组口服三子止咳胶囊,对照组口服安慰剂,均2粒/次,3次/d,治疗6个月。分别于治疗前及治疗6个月,应用肺功能检测仪检测第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1占预计值百分比(FEV1%pred),测定患者血清脂联素(APN)、白细胞介素17(IL-17)、基质金属蛋白酶9(MMP-9)、基质金属蛋白酶抑制剂1(TIMP-1)水平。结果与治疗前比较,治疗6个月对照组FVC、FEV_1、FEV1%pred及血清APN、IL-17、MMP-9、TIMP-1水平比较差异无统计学意义(P均0.05),观察组以上指标均改善(P均0.05),治疗6个月两组以上指标比较差异有统计学意(P均0.05)。结论三子止咳胶囊对COPD稳定期患者的肺功能有改善作用,该作用可能与降低血清APN、IL-17、MMP-9、TIMP-1水平有关。
[Abstract]:Objective to observe the effect of Sanzi Zhike capsule on pulmonary function in patients with chronic obstructive pulmonary disease (COPD) in stable stage and to explore its possible mechanism. Methods Sixty-eight patients with stable COPD were randomly divided into observation group (n = 33) and control group (n = 35). The observation group was treated with Sanzi Zhike capsule and the control group with placebo for 6 months. The forced respiratory volume (FEV1) in the first second and the percentage of forced vital capacity (FVC), FEV1) to the predicted value (FEV1%pred) were measured by pulmonary function detector before and 6 months after treatment, and serum adiponectin (APN), was measured. The levels of IL-17 (IL-17), matrix metalloprotease 9 (MMP-9) and matrix metalloprotease inhibitor 1 (TIMP-1). Results there was no significant difference in FVC,FEV_1,FEV1%pred and serum APN,IL-17,MMP-9,TIMP-1 levels between the control group and the control group after 6 months of treatment. The above indexes were improved in the observation group (P 0.05), and there were statistical differences between the two groups after 6 months of treatment (P 0.05). Conclusion Sanzizhike capsule can improve the pulmonary function of patients with stable COPD, which may be related to the decrease of serum APN,IL-17,MMP-9,TIMP-1 level.
【作者单位】：潍坊医学院;潍坊医学院附属医院;
【基金】：山东省中医药科技发展计划项目(2011-222)
【分类号】：R563.9

【参考文献】